A Statement from the CEO of FARE
The recent concerns raised about epinephrine pricing practices have led to questions on FARE’s relationship with commercial organizations. As CEO of FARE I think it’s important to address these questions.
Careful not to name Mylan specifically, but good to know: “We have therefore decided that until meaningful competition exists in the epinephrine auto-injector space we will no longer accept donations from companies marketing these devices.”